Dilated Cardiomyopathy Affects Several Individual around the World Each Year After an Illness Such As Viral Infection Or Pregnancy

 

Dilated Cardiomyopathy

Dilated cardiomyopathy can cause heart failure and require a heart transplant. However, with proper treatment and monitoring, the symptoms of this disease can be controlled and the chance of its progression reduced. A diagnosis of dilated cardiomyopathy is usually made within the first year. Symptoms of dilated cardiomyopathy may appear gradually over several months, or they may develop suddenly after an illness, like pregnancy or a viral infection.

Dilated cardiomyopathy is the most common type of cardiomyopathy and affects both the lower and upper chambers of the heart. This condition often starts in the left ventricle, where the heart muscle thins and dilates. As the disease progresses, it spreads to the right ventricle and atria, where it can cause heart failure. If left untreated, the condition can lead to heart failure and sudden cardiac arrest.

According to Coherent Market Insights the Dilated Cardiomyopathy Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Treatment for dilated cardiomyopathy includes dilation of peripheral blood vessels. This reduces the workload on the heart and helps the heart pump more effectively. Moreover, cardiac medications are often used to improve systolic function and reduce ventricular workload. These drugs are also used to control heart rate and cardiac arrhythmias. DCM treatment can involve either or both of these procedures. 

Infections account for about 30% of DCM etiology. Most commonly, these infections are associated with myocarditis. Animal models and patients have shown that infections can cause this condition. This disease has been linked with increased incidences of autoimmunity and inflammation. Furthermore, infection-related DCM may require the use of a special type of drugs to treat this condition. However, the best treatment depends on the type of infection.

Along with genetic aetiology, DCM should be evaluated in patients with first-degree relatives. A detailed family history and clinical screening of first-degree relatives are essential to a definitive diagnosis. Next-generation sequencing methods are emerging as inexpensive diagnostic tools with both research and clinical implications. These advances will allow doctors to create personalized risk stratification schemes, combining genetic information with additional clinical factors. Once the results of these tests are available, the disease can be diagnosed and treated. In June 2021, Nuevocor, a preclinical-stage biotech company head quartering in Singapore that specializes in gene therapy for cardiomyopathies announced that the company has completed US$ 24 million Series A financing round.